Education
About Us
Working with TipRanks
Follow Us
FSZ - ETF AI Analysis
Top Page
First Trust Switzerland AlphaDEX Fund (FSZ)
Rating:63Neutral
Price Target:―
Positive Factors
Improving Recent Performance
The ETF has shown solid gains over the last three months and slightly positive results so far this year, indicating improving momentum.
Supportive Top Holdings
Several of the largest positions, such as Sandoz, Roche, and EFG International, have delivered strong year-to-date performance, helping support the fund’s returns.
Diversified Swiss Sector Exposure
Holdings spread across health care, industrials, financials, and consumer-related sectors help reduce the impact of weakness in any single industry within Switzerland.
Negative Factors
High Country Concentration
With the vast majority of assets invested in Swiss companies, the fund is heavily exposed to economic and market conditions in Switzerland.
Weakness in Several Top Holdings
A number of major positions, including Holcim, Barry Callebaut, Galenica, Adecco, Bucher Industries, and Galderma, have shown weak year-to-date performance, which can drag on overall returns.
Relatively High Expense Ratio
The fund’s expense ratio is on the higher side for an ETF, which means more of the investment return is used to cover fees.
FSZ vs. SPDR S&P 500 ETF (SPY)
AUM42.98M
RegionEurope
Expense Ratio0.80%
Beta0.63
IssuerFirst Trust
Inception DateFeb 14, 2012
Dividend Yield1.68%
Asset ClassEquity
Index TrackedNASDAQ AlphaDEX Switzerland Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume5,073
30 Day Avg. Volume2,030
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
88.55Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering40
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FSZ Summary
FSZ is an exchange-traded fund that follows the NASDAQ AlphaDEX Switzerland Index, giving you broad exposure to Swiss stocks. It focuses on many types of companies, including health care, industrials, and financials. Well-known names in the fund include Roche Holding and Holcim. Someone might invest in FSZ to diversify outside the U.S. and tap into Switzerland’s mix of stable, defensive businesses and growth opportunities. A key risk is that the fund is concentrated in one country, so its value can rise or fall with the Swiss stock market and economy.
How much will it cost me?The expense ratio for the First Trust Switzerland AlphaDEX Fund (FSZ) is 0.8%, which means you’ll pay $8 per year for every $1,000 invested. This is higher than the average for ETFs because it is actively managed, using a rules-based strategy to select stocks with growth and value potential. Actively managed funds typically have higher costs due to the additional research and management involved.
What would affect this ETF?The FSZ ETF, which focuses on Swiss equities, could benefit from Switzerland's strong reputation for economic stability and innovation, particularly in sectors like healthcare and finance. Positive trends such as advancements in pharmaceuticals or growth in financial services could drive the ETF's performance. However, potential risks include economic slowdowns in Europe, regulatory changes affecting key sectors, or global market volatility, which could negatively impact the ETF's holdings and overall returns.
FSZ Top 10 Holdings
FSZ is leaning into Switzerland’s industrial and health-care backbone, with names like Sandoz and Roche doing much of the heavy lifting as their shares keep rising on solid momentum and strong fundamentals. Financial player EFG International is also pulling its weight, adding a value-and-income tilt. On the flip side, staffing giant Adecco and machinery maker Bucher Industries have been lagging, acting as a bit of a brake on returns, while consumer-focused Barry Callebaut looks mixed. Overall, it’s a Switzerland-centric, sector-diversified bet with no single stock dominating the story.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Sandoz Group Ltd | 4.61% | $1.89M | CHF29.34B | 85.40% | 59 Neutral | |
| SFS Group AG | 4.53% | $1.86M | CHF4.78B | 5.28% | 72 Outperform | |
| Barry Callebaut AG | 4.43% | $1.82M | CHF7.85B | 37.20% | 54 Neutral | |
| Bucher Industries AG | 4.16% | $1.71M | CHF3.93B | 1.72% | 65 Neutral | |
| Galenica AG | 4.12% | $1.69M | CHF5.08B | 23.61% | 70 Outperform | |
| Swisscom AG | 3.89% | $1.60M | CHF36.39B | 40.81% | 67 Neutral | |
| Galderma Group AG | 3.78% | $1.55M | CHF36.66B | 35.57% | 70 Outperform | |
| Holcim | 3.77% | $1.55M | CHF39.33B | -22.44% | 73 Outperform | |
| Adecco Group AG | 3.71% | $1.52M | CHF3.63B | -6.83% | 65 Neutral | |
| Roche Holding AG | 3.57% | $1.46M | CHF294.84B | 46.01% | 73 Outperform |
FSZ Technical Analysis
Positive
―
Price Trends
81.87
Positive
79.29
Positive
77.87
Positive
Market Momentum
1.20
Negative
66.89
Neutral
95.48
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FSZ, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 84.32, equal to the 50-day MA of 81.87, and equal to the 200-day MA of 77.87, indicating a bullish trend. The MACD of 1.20 indicates Negative momentum. The RSI at 66.89 is Neutral, neither overbought nor oversold. The STOCH value of 95.48 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FSZ.
FSZ Peer Comparison
Comparison Results
Performance Comparison
FSZ
First Trust Switzerland AlphaDEX Fund
85.87
19.69
29.75%
EWL
iShares MSCI Switzerland ETF
―
―
―
FLSW
Franklin FTSE Switzerland ETF
―
―
―
EUDG
WisdomTree Europe Quality Dividend Growth Fund
―
―
―
FLEU
Franklin FTSE Eurozone ETF
―
―
―
DBEZ
Xtrackers MSCI Eurozone Hedged Equity ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents